Genelux

Focus: Genelux is a biotechnology company focused on oncolytic virus therapeutics for solid organ cancers, operating from California with a specialized pipeline in immuno-oncology.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Genelux

AI assessmentNot Hiring

No open roles listed right now. Follow Genelux to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

GL-ONC1

Advanced Stage Cancer (Solid Tumor Disease for 4 Patients)

N/A

Clinical Trials (1)

NCT03420430Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care

N/A

Help build intelligence for Genelux

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Deep pipeline focus: 10 active trials across Phase 1-3 with one Phase 3 program (olvimulogene nanivacirepvec in platinum-resistant ovarian cancer) offering near-term clinical catalysts
Specialized expertise in oncolytic viruses—a differentiated modality with fewer competitors, enabling rare technical depth in your field
Early-stage biotech stage allows direct impact on drug development and potential equity upside if pipeline advances

Watch Out For

No active job openings (0 roles) and minimal public hiring activity suggests limited near-term expansion or possible funding constraints
Early-stage pipeline (7 Phase 1 programs) means extended timelines to value inflection; regulatory and clinical risks remain high
Limited public financial data, employee count, and funding transparency create uncertainty around company stability and runway

Generated by Claude from Genelux's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

GL-ONC1

Lung Cancer

Phase 1

Clinical Trials (1)

NCT01766739Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma

Phase 1

GL-ONC1

Solid Organ Cancers

Phase 1

Clinical Trials (1)

NCT02714374GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers

Phase 1

GL-ONC1

Advanced Cancers (Solid Tumors)

Phase 1

Clinical Trials (1)

NCT00794131Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors

Phase 1

GL-ONC1

Cancer of Head and Neck

Phase 1

Clinical Trials (1)

NCT01584284Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer

Phase 1

GL-ONC1

Peritoneal Carcinomatosis

Phase 1/2

Clinical Trials (1)

NCT01443260A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis

Phase 1/2

GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab

Ovarian Cancer

Phase 1/2

Clinical Trials (1)

NCT02759588GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Phase 1/2

Olvi-Vec

SCLC, Extensive Stage

Phase 1/2

Clinical Trials (1)

NCT07136285Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC

Phase 1/2

Olvimulogene nanivacirepvec

Advanced Non-squamous Non-small-cell Lung Cancer

Phase 2

Clinical Trials (1)

NCT06463665Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Phase 2

olvimulogene nanivacirepvec

Platinum-resistant Ovarian Cancer

Phase 3

Clinical Trials (1)

NCT05281471Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 10 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

9 pipeline

Marketed

Pipeline